Exabis Library
Welcome to the e-CCO Library!
DOP54: Efficacy and safety of ustekinumab through week 16 in patients with moderate to severe ulcerative colitis randomised to ustekinumab: Results from the UNIFI induction trial
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP54: Integrated network analysis using patient-specific single nucleotide polymorphism profiles uncovers new pathways involved in Ulcerative Colitis pathogenesis
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP55: ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases using whole-exome sequencing
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP55: A real-world comparison of the effectiveness and safety of vedolizumab and anti-TNF therapies in early treatment initiation with first-line biologic therapy in Ulcerative Colitis: Results from EVOLVE
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP56: Ustekinumab maintained clinically meaningful improvement in health-related quality of life in patients with moderate to severe Ulcerative Colitis: Results from the UNIFI long-term extension
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP57: Monitoring response to anti-TNF therapy in ulcerative colitis patients by gastrointestinal ultrasound: sub-analysis from TRUST UC
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP57: Vedolizumab has similar efficacy rates in young and elderly patients: A binational, multicenter, retrospective case-control study
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP58: IDeaL – a multi-center prospective Infliximab Dose to Level pharmacokinetic study during induction in pediatric Crohn’s disease
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP58: Tofacitinib for Ulcerative Colitis: Results of the ICC Registry, a nationwide prospective observational cohort study
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP59: Maintenance of remission with tofacitinib in patients with Ulcerative Colitis: Updated results of a subpopulation analysis from an open-label, long-term extension study, OCTAVE Open
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP59: Proactive Infliximab Drug Monitoring Is Superior To Conventional Management In Inflammatory Bowel Disease
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP60: Vedolizumab treatment persistence and safety in an extended access program (XAP)
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP61: A nationwide cohort study of colectomy rates for ulcerative colitis during the introduction of biologic therapy
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP61: Tofacitinib, an oral, small molecule Janus kinase inhibitor, in the treatment of Ulcerative Colitis: Analysis of an open-label, long-term extension study with up to 5.9 years of treatment
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP62: A Novel Formulation of CT-P13 (Infliximab Biosimilar) for Subcutaneous Administration: 1-Year Result from a Phase I Open-label Randomised Controlled Trial in Patients with Active Crohn’s Disease
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP62: Morbidity after primary ileocecal resection for Crohn’s Disease in the years of biologics: Lesson learned over 631 patients exclusively treated in a tertiary centre
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP63: Adalimumab for patients with Crohn’s disease complicated by intra-abdominal abscess: a multicentre, prospective, observational cohort study
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP63: Efficacy and safety of iron carboxymaltose on chronic fatigue in patients with Inflammatory Bowel Disease: A randomized controlled trial
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP64: Discovery of highly selective small molecule oral inhibitors of integrin α4β7 for the treatment of Inflammatory Bowel Diseases
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP64: Minimal additional benefits in adding fecal hemoglobin to fecal calprotectin in predicting endoscopic disease activity in patients with inflammatory bowel disease
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1